SOX10 and neoplasm: Given that this reprogramming process may be driven by the genomic retargeting of SOX10, TFAP2A and MITF to EWSR1-ATF1 binding sites, retargeting these TFs to induce a melanocytic phenotype could constitute an effective therapeutic strategy, allowing tumor cells to differentiate and become more chemo-sensitive and possibly immunogenic.